Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Importance Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node
staging of patients with early breast cancer (BC), but its necessity can be questioned since …

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced
breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine …

Background We aimed to report on long-term outcomes of patients with small, node-
negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and …

Cytotoxic drugs have long been recognised to kill cancer cells through apoptosis. According
to a current study, pyroptosis inhibits cell proliferation and shrinks tumors. Pyroptosis and …

Background Anthracycline–taxane chemotherapy for early-stage breast cancer substantially
improves survival compared with no chemotherapy. However, concerns about short-term …

Our previous studies have showed that CC motif chemokine ligand 20 (CCL20) advanced
tumor progression and enhanced the chemoresistance of cancer cells by positively …

Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-
positive expression. We recently described a high instability of HER2-low-positive …

The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna,
Austria, assessed significant new findings for local and systemic therapies for early breast …